• Denisa BOROS Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Teodora ALEXA-STRATULAT Grigore T. Popa” University of Medicine and Pharmacy Iasi


Although malignant melanoma accounts for less than 5% of all cancers, it is one of the most aggressive types of cancer, associated with a poor outcome. Survival rates significantly vary according to stage and even within the same stage there are significant survival differences. The aim of this study was to assess the role of red cell distribution width (RDW) as a potential prognosis factor for malignant melanoma. Also, this analysis aims to determine average survival and the time until relapse/progression of the disease in patients with malignant melanoma treated at the Regional Institute of Oncology Iasi (IRO) between 2013 and 2016. Materials and methods: We performed a retrospective analysis of melanoma patients treated in the IRO between 2013 and 2016. We collected several parameters including age, sex, tumor localization, clinical and pathological stage, Breslow Index, Clark level, ulceration and detailed therapeutic management. We then analyzed each parameter to assess its impact on progression-free survival and overall survival. Results: We identified RDW as a significant prognosis marker, with worse outcome for patients with abnormal RDW values. Additionally, tumor localization, Clark level, Breslow index and cancer stage also showed prognosis value. Conclusions: RDW is a useful, inexpensive prognosis marker that can better predict survival. Prospective studies are required for confirming the findings of the present analysis.

Author Biographies

Denisa BOROS, Grigore T. Popa” University of Medicine and Pharmacy Iasi

Regional Institute of Oncology
Medical Oncology Department, Iasi

Teodora ALEXA-STRATULAT, Grigore T. Popa” University of Medicine and Pharmacy Iasi

Regional Institute of Oncology
Medical Oncology Department, Iasi


lie AC, Alexa ID, Morosanu AI, Covic A, Cepoi V. Effects of oxidative stress and pharmacological treatment on geriatric syndromes in the hospitalized elderly patients. Farmacia 2016; 64(4): 588-593.
2. Gafton B, Porumb V, Ungurianu S, Marinca MV, Cocea C, Croitoru A, et al. Hepatocellular carcino-ma: insights in the biological treatment beyond sorafenib. J BUON 2014; 19(4): 858-866.
3. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27(1): 3-9.
4. Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer 2015; 121(23): 4108-4123.
5. Azoury SC, Lange JR. Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma. Surg Clin North Am 2014; 94(5): 945-962.
6. Berrocal A, Cabañas L, Espinosa E, Fernández-de-Misa R, Martín-Algarra S, Martínez-Cedres JC, et al. Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Adv Ther 2014; 31(9): 945-960.
7. Cireap N, Narita D. Molecular profiling of ADAM12 and ADAM17 genes in human malignant mela-noma. Pathol Oncol Res 2013; 19(4): 755-762.
8. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363(8):711-723.
9. DeVita VTJ, Lawrence TS, Rosenberg SA, editors. Principles & Practice of Oncology 10th Edition. 10th ed. Philadelphia: Wolters Kluwer; 2015.
10. Baade PD, Royston P, Youl PH, Weinstock MA, Geller A, Aitken JF. Prognostic survival model for people diagnosed with invasive cutaneous melanoma. BMC Cancer. 2015;15(1):27-32.
11. Mandalà M, Massi D. Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch. 2014;464(3):265-281.
12. Miron I, Diaconescu S, Aprodu G, Ioniuc I, Diaconescu MR, Miron L. Diagnostic Difficulties in a Pediatric Insulinoma: A Case Report. Medicine (Baltimore) 2016; 95(11): e3045.
13. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19(16): 3622-3634.
14. Cobzeanu MD, Costinescu V, Rusu CD, Mihailovici S, Grigoras M, Miron L, et al. Laryngotracheal non-Hodgkin’s lymphoma. Chirurgia (Bucur) 2010; 105(1): 131-136.
15. Abbas O, Miller DD, Bhawan J. Cutaneous Malignant Melanoma. Am J Dermatopathol 2014; 36(5): 363-379.
16. Gerber IC, Mihai CT, Gorgan L, Ciorpac M, Nita A, Pohoata V, et al. Viability and Cell Biology for HeLa and Vero Cells after Exposure to Low-Temperature Air Dielectric Barrier Discharge Plasma. Plasma Med. Begel House Inc. 2017; 7(2): 159-173.
17. Balan V, Dodi G, Tudorachi N, Ponta O, Simon V, Butnaru M, et al. Doxorubicin-loaded magnetic nanocapsules based on N-palmitoyl chitosan and magnetite: Synthesis and characterization. Chem Eng J. Elsevier 2015; 279: 188-197.
18. Wevers KP, Kruijff S, Speijers MJ, Bastiaannet E, Muller Kobold AC, Hoekstra HJ. S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB-C Melanoma. Ann Surg Oncol 2013; 20(8): 2772-2779.
19. Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. J Natl Cancer Inst 2015; 107(12): djv264.
20. Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappalà A, Annessi G, et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res 2015; 25(4): 306-311.
21. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci 2015; 52(2): 86-105.
22. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased Red Blood Cell Distribution Width Associates with Cancer Stage and Prognosis in Patients with Lung Cancer. Katoh M, editor. PLoS One. 2013; 8(11): e80240.
23. Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. Red cell distribution width as a predictor of prostate cancer progression. Asian Pac J Cancer Prev. 2014; 15(18):7781-7784.
24. Kemal Y, Demirag G, Baş B, Önem S, Teker F, Yücel İ. The value of red blood cell distribution width in endometrial cancer. Clin Chem Lab Med. 2015; 53(5): 823-827.
25. Zhao T, Cui L, Li A. The significance of RDW in patients with hepatocellular carcinoma after radical resection. Cancer Biomarkers. 2016; 16(4): 507-512.
26. Crocetti E, Fancelli L, Manneschi G, Caldarella A, Pimpinelli N, Chiarugi A, et al. Melanoma survival. Eur J Cancer Prev. 2016;25(5):404-409.
27. Alexa ID, Ilie AC, Moroşanu A, Stamos EP, Räihä I. Self - neglect in elders: a worldwide issue ig-nored in Romania. Rev Rom Bioet 2012; 10(1): 141-148.
28. Cepoi V, Alexa ID, Ilie AC, Alexa O. Ethical dilemmas in treating elderly patients at risk of poly-pragmasy and polypharmacy. Rev Rom Bioet. 2014; 12(3): 12-18.
29. Alexa O, Veliceasa B, Malancea R, Alexa ID. Postoperative cognitive disorder has to be included within informed consent of elderly patients undergoing total hip replacement. Rev Rom Bioet. 2013; 11(4): 40-49.
30. Johnson-Obaseki SE, Labajian V, Corsten MJ, McDonald JT. Incidence of cutaneous malignant melanoma by socioeconomic status in Canada: 1992-2006. J Otolaryngol Head Neck Surg. 2015; 44(1): 53-57.
31. Callender GG, Egger ME, Burton AL, Scoggins CR, Ross MI, Stromberg AJ, et al. Prognostic impli-cations of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg. 2011; 202(6): 659-665.
32. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF. SEER cancer statistics review, 1975-2013. Bethesda, National Cancer Institute; 2015.
33. Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. Clin Epidemiol 2016; 8: 109-122.
34. Tas F. Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors. J Oncol. 2012; 2012: 1-9.
35. Yilmaz A, Malya F, Ozturk G, Citgez B, Ozdenkaya Y, Ersavas C, et al. Effect of pre-operative red blood cell distribution on cancer stage and morbidity rate in patients with pancreatic cancer. Int J Clin Exp Med. 2014; 7(9): 3072-3075.
36. Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther. 2014; 7: 1743-1752.
37. Avilés-Izquierdo JA, Lázaro-Ochaita P. Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. Clin Transl Oncol 2012; 14(3): 237-240.
38. Weide B, Elsässer M, Büttner P, Pflugfelder A, Leiter U, Eigentler TK, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 2012; 107(3): 422-428.
39. Palmer SR, Erickson LA, Ichetovkin I, Knauer DJ, Markovic SN. Circulating Serologic and Molecular Biomarkers in Malignant Melanoma. Mayo Clin Proc 2011; 86(10): 981-990.
40. Ababei DC, Chiriac Beschea S, Bild W, Solcan C, Luca A, Rusu RN, et al. Synergistic effects of the doxepin-candesartan combination on the thermoalgesic sensibility in mice. Farmacia 2017; 65(5): 726-730.
41. Bild V, Ababei DC, Neamtu M, Vasincu A, Bild W, Stanciu GD, et al. Isobolar analysis of the binary fixed-ratio combination of acetylsalicilic acid-acetaminophen. Farmacia 2017; 65(4): 563-566.